6C1 Stock Overview An oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
CytomX Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for CytomX Therapeutics Historical stock prices Current Share Price US$0.89 52 Week High US$4.40 52 Week Low US$0.77 Beta 1.01 1 Month Change -16.53% 3 Month Change -11.89% 1 Year Change -32.24% 3 Year Change -77.98% 5 Year Change -86.26% Change since IPO -90.47%
Recent News & Updates
New major risk - Revenue and earnings growth Jan 07
Third quarter 2024 earnings released: EPS: US$0.067 (vs US$0.037 in 3Q 2023) Nov 08
CytomX Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 31
Investor sentiment improves as stock rises 18% Sep 11
Second quarter 2024 earnings released: US$0.077 loss per share (vs US$0.016 loss in 2Q 2023) Aug 09
New minor risk - Market cap size Aug 06 See more updates
New major risk - Revenue and earnings growth Jan 07
Third quarter 2024 earnings released: EPS: US$0.067 (vs US$0.037 in 3Q 2023) Nov 08
CytomX Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 31
Investor sentiment improves as stock rises 18% Sep 11
Second quarter 2024 earnings released: US$0.077 loss per share (vs US$0.016 loss in 2Q 2023) Aug 09
New minor risk - Market cap size Aug 06
CytomX Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
Investor sentiment improves as stock rises 15% Jul 18
Investor sentiment deteriorates as stock falls 15% Jun 19
CytomX Therapeutics, Inc. Promotes Chris Ogden to Chief Financial Officer Jun 18
Investor sentiment deteriorates as stock falls 54% May 15
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager) May 10
First quarter 2024 earnings released: EPS: US$0.17 (vs US$0.05 loss in 1Q 2023) May 09
CytomX Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-2051, A Conditionally Activated EpCAM-Directed ADC, in A Phase 1 Study in Patients with Advanced Solid Tumors Apr 09
CytomX Therapeutics, Inc., Annual General Meeting, May 15, 2024 Apr 05
CytomX Therapeutics, Inc. Appoints Dr. Zhen Su to Board of Directors Mar 21
Full year 2023 earnings released: US$0.008 loss per share (vs US$1.51 loss in FY 2022) Mar 12
CytomX Therapeutics, Inc. to Report Q4, 2023 Results on Mar 11, 2024 Mar 05
New minor risk - Market cap size Feb 03
CytomX Therapeutics, Inc. Announces FDA Clearance of IND Applications for CX-2051, a Probody Antibody Drug Conjugate Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b Jan 24
New minor risk - Profitability Jan 07
Forecast breakeven date pushed back to 2024 Dec 31
Third quarter 2023 earnings released: EPS: US$0.037 (vs US$0.35 loss in 3Q 2022) Nov 10
Forecast to breakeven in 2023 Nov 08
CytomX Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Nov 01
CytomX Therapeutics, Inc. Presents Preclinical Profile of EpCAM-Directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference Oct 19 CytomX Therapeutics, Inc. announced that it has received $30 million in funding Aug 19
New minor risk - Market cap size Aug 18
Second quarter 2023 earnings released: US$0.016 loss per share (vs US$0.37 loss in 2Q 2022) Aug 09
CytomX Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Aug 03
CytomX Therapeutics, Inc. Appoints Yu-Waye Chu as Chief Medical Officer Jul 21
New minor risk - Market cap size Jun 29
First quarter 2023 earnings released: US$0.05 loss per share (vs US$0.36 loss in 1Q 2022) May 11
Full year 2022 earnings released: US$1.51 loss per share (vs US$1.81 loss in FY 2021) Apr 02
High number of new and inexperienced directors Nov 16
Third quarter 2022 earnings released: US$0.35 loss per share (vs US$0.35 loss in 3Q 2021) Nov 10
CytomX Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Nov 02 CytomX Therapeutics, Inc. Announces Executive Changes
Second quarter 2022 earnings released: US$0.37 loss per share (vs US$0.30 loss in 2Q 2021) Aug 05
CytomX Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29 Cytomx Therapeutics, Inc. to Terminate Carlos Campoy as Chief Financial Officer, Effective as of September 30, 2022
CytomX Therapeutics, Inc. Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer Jul 07
CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors May 27
First quarter 2022 earnings released: US$0.36 loss per share (vs US$0.26 loss in 1Q 2021) May 07
High number of new directors Apr 27
Cytomx Therapeutics Announces Retirement of John A. Scarlett from Board of Directors and Chair of the Compensation Committee and A Member of the Audit Committee Apr 16
CytomX Therapeutics, Inc., Annual General Meeting, Jun 15, 2022 Apr 15
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 03
CytomX Therapeutics, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 24
Cytomx Therapeutics, Inc. Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating Officer Feb 08
CytomX Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors Jan 20
CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029 Dec 21
Third quarter 2021 earnings released: US$0.35 loss per share (vs US$0.32 loss in 3Q 2020) Nov 06
Second quarter 2021 earnings released: US$0.30 loss per share (vs US$0.34 loss in 2Q 2020) Aug 08
CytomX Therapeutics, Inc. Announces Publication of First-in-Human Data for CX-2029 in Clinical Cancer Research Jun 22
First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.27 profit in 1Q 2020) May 07
Full year 2020 earnings released: US$0.71 loss per share (vs US$2.26 loss in FY 2019) Feb 26
Revenue beats expectations Feb 26
CytomX Therapeutics, Inc. to Report Q4, 2020 Results on Feb 24, 2021 Feb 18
New 90-day high: €7.42 Feb 10
New 90-day high: €6.65 Jan 19
CytomX Therapeutics, Inc. Appoints Dr. Mani Mohindru to Board of Directors Dec 25
New 90-day high: €6.60 Dec 16
Revenue beats expectations Nov 07
Third quarter 2020 earnings released: US$0.32 loss per share Nov 07
CytomX Therapeutics, Inc. Announces Treatment of First Patient in Phase 2 Expansion Study of CX-2029, an Anti-CD71 Probody Drug Conjugate Nov 06
CytomX Therapeutics, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 30
CytomX Therapeutics, Inc. Announces Planned Retirement of W. Michael Kavanaugh, Chief Scientific Officer, Head of Research and Non-Clinical Development on December 1, 2020 Oct 07
New 90-day low - €5.55 Sep 05
First half earnings released Aug 07
New 90-day low - €6.40 Jul 30 Shareholder Returns 6C1 DE Biotechs DE Market 7D 15.8% 2.3% 0.5% 1Y -32.2% -2.6% 15.3%
See full shareholder returns
Return vs Market: 6C1 underperformed the German Market which returned 13.7% over the past year.
Price Volatility Is 6C1's price volatile compared to industry and market? 6C1 volatility 6C1 Average Weekly Movement 14.4% Biotechs Industry Average Movement 6.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 6C1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6C1's weekly volatility has decreased from 27% to 14% over the past year, but is still higher than 75% of German stocks.
About the Company CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine.
Show more CytomX Therapeutics, Inc. Fundamentals Summary How do CytomX Therapeutics's earnings and revenue compare to its market cap? 6C1 fundamental statistics Market cap €70.64m Earnings (TTM ) €13.31m Revenue (TTM ) €121.89m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 6C1 income statement (TTM ) Revenue US$126.62m Cost of Revenue US$0 Gross Profit US$126.62m Other Expenses US$112.79m Earnings US$13.83m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/06 10:53 End of Day Share Price 2025/02/06 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources CytomX Therapeutics, Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Peter Lawson Barclays Etzer Darout BMO Capital Markets Equity Research Ying Huang BofA Global Research
Show 14 more analysts 
